Novo Nordisk Stock Options

NVO Stock  USD 75.89  1.10  1.47%   
Novo Nordisk's latest option contracts expiring on June 20th 2025 are carrying combined implied volatility of 0.63 with a put-to-call open interest ratio of 0.79 over 65 outstanding agreements suggesting investors are buying slightly more calls than puts on contracts expiring on June 20th 2025. The total put volume is at 354, with calls trading at the volume of 1.4 K. This yields a 0.25 put-to-call volume ratio.

Open Interest Against June 20th 2025 Option Contracts

The chart above shows Novo Nordisk's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Novo Nordisk's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Novo Nordisk's option, there is no secondary market available for investors to trade.

Novo Nordisk Maximum Pain Price Across 2025-06-20 Option Contracts

Max pain occurs when Novo Nordisk's market makers reach a net positive position across all Novo Nordisk's options at a strike price where option holders stand to lose the most money. By contrast, Novo Nordisk's option sellers may reap the most after selling more options than buying, causing them to expire worthless.

In The Money vs. Out of Money Option Contracts on Novo Nordisk

Analyzing Novo Nordisk's in-the-money options over time can help investors to take a profitable long position in Novo Nordisk regardless of its overall volatility. This is especially true when Novo Nordisk's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Novo Nordisk's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Novo Nordisk's stock while costing only a fraction of its price.
Please note that buying 'in-the-money' options on Novo Nordisk lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Novo Nordisk's value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Novo Nordisk contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Novo Stock moves the wrong way.

Novo Nordisk AS In The Money Call Balance

When Novo Nordisk's strike price is surpassing the current stock price, the option contract against Novo Nordisk AS stock is said to be in the money. When it comes to buying Novo Nordisk's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Novo Nordisk AS are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Novo Current Options Market Mood

Novo Nordisk's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Novo Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Novo Nordisk's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Novo Nordisk's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Novo contract

Base on the Rule 16, the options market is currently suggesting that Novo Nordisk AS will have an average daily up or down price movement of about 0.0394% per day over the life of the 2025-06-20 option contract. With Novo Nordisk trading at USD 75.89, that is roughly USD 0.0299. If you think that the market is fully incorporating Novo Nordisk's daily price movement you should consider buying Novo Nordisk AS options at the current volatility level of 0.63%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing Novo Nordisk options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Novo calls. Remember, the seller must deliver Novo Nordisk AS stock to the call owner when a call is exercised.

Novo Nordisk Option Chain

When Novo Nordisk's strike price is surpassing the current stock price, the option contract against Novo Nordisk AS stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Novo Nordisk's option chain is a display of a range of information that helps investors for ways to trade options on Novo. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Novo. It also shows strike prices and maturity days for a Novo Nordisk against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
NVO250620C00200000523200.00.03 - 0.320.08Out
Call
NVO250620C001950001195.00.03 - 0.350.4Out
Call
NVO250620C0019000030190.00.04 - 0.360.2Out
Call
NVO250620C001850001185.00.04 - 0.360.35Out
Call
NVO250620C0018000016180.00.05 - 0.380.19Out
Call
NVO250620C00175000126175.00.05 - 0.390.25Out
Call
NVO250620C00170000157170.00.05 - 0.390.14Out
Call
NVO250620C0016500056165.00.07 - 0.210.19Out
Call
NVO250620C00160000296160.00.06 - 0.370.19Out
Call
NVO250620C00155000225155.00.1 - 0.430.18Out
Call
NVO250620C00150000751150.00.08 - 0.20.16Out
Call
NVO250620C00145000682145.00.09 - 0.230.18Out
Call
NVO250620C00140000269140.00.2 - 0.450.2Out
Call
NVO250620C00135000437135.00.18 - 0.30.2Out
Call
NVO250620C001300001259130.00.25 - 0.510.25Out
Call
NVO250620C001250001726125.00.16 - 0.560.37Out
Call
NVO250620C001200001993120.00.35 - 0.490.41Out
Call
NVO250620C001150005142115.00.43 - 0.550.18Out
Call
NVO250620C001100002597110.00.57 - 0.670.63Out
Call
NVO250620C001050004447105.00.75 - 0.860.77Out
Call
NVO250620C001000003911100.01.04 - 1.161.08Out
Call
NVO250620C00095000546195.01.51 - 1.581.58Out
Call
NVO250620C00090000371890.02.21 - 2.442.31Out
Call
NVO250620C00085000270185.03.25 - 3.43.3Out
Call
NVO250620C0008000077980.04.7 - 4.94.9Out
Call
NVO250620C0007500055175.06.7 - 6.96.78Out
Call
NVO250620C0007000021570.09.3 - 9.559.48In
Call
NVO250620C000650002565.012.4 - 12.812.75In
Call
NVO250620C000600005960.016.2 - 16.7516.5In
Call
NVO250620C00055000755.020.35 - 21.0520.69In
Call
NVO250620C000500001050.024.85 - 25.540.28In
Call
NVO250620C00045000845.029.6 - 30.6529.94In
Call
NVO250620C00040000240.034.55 - 37.135.4In
 Put
NVO250620P0020000036200.0125.0 - 125.9113.0In
 Put
NVO250620P0019500068195.0120.2 - 120.9108.0In
 Put
NVO250620P0019000063190.0115.3 - 115.9102.95In
 Put
NVO250620P0018500057185.0110.2 - 111.2598.05In
 Put
NVO250620P00180000101180.0105.1 - 106.1106.15In
 Put
NVO250620P0017500039175.0100.05 - 100.95101.1In
 Put
NVO250620P0017000014170.095.2 - 96.092.35In
 Put
NVO250620P0016500020165.089.9 - 91.0590.75In
 Put
NVO250620P00160000111160.085.4 - 86.1585.75In
 Put
NVO250620P0015500031155.080.35 - 81.081.1In
 Put
NVO250620P0015000014150.074.45 - 76.0572.45In
 Put
NVO250620P0014500019145.070.25 - 71.171.4In
 Put
NVO250620P00140000134140.064.95 - 66.166.45In
 Put
NVO250620P00135000158135.059.75 - 62.257.0In
 Put
NVO250620P0013000061130.054.55 - 56.1550.55In
 Put
NVO250620P0012500068125.049.85 - 51.151.55In
 Put
NVO250620P00120000327120.045.25 - 46.246.3In
 Put
NVO250620P00115000931115.040.15 - 41.341.4In
 Put
NVO250620P001100002322110.035.65 - 36.4535.85In
 Put
NVO250620P00105000788105.030.9 - 31.430.65In
 Put
NVO250620P001000001616100.025.35 - 26.5525.95In
 Put
NVO250620P00095000381095.021.6 - 21.9521.85In
 Put
NVO250620P00090000315290.017.2 - 17.6517.1In
 Put
NVO250620P00085000339285.013.15 - 13.614.0In
 Put
NVO250620P00080000367280.09.05 - 10.159.79In
 Put
NVO250620P00075000463075.06.8 - 7.06.92Out
 Put
NVO250620P00070000210370.04.4 - 4.64.6Out
 Put
NVO250620P00065000150765.02.76 - 2.852.81Out
 Put
NVO250620P0006000033660.01.51 - 1.641.55Out
 Put
NVO250620P0005500010055.00.77 - 0.920.84Out
 Put
NVO250620P000500004950.00.21 - 0.480.47Out
 Put
NVO250620P0004500031445.00.1 - 0.320.23Out

Novo Nordisk Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

Novo Nordisk Market Cap Over Time

   Market Cap   
       Timeline  

Novo Total Stockholder Equity

Total Stockholder Equity

150.66 Billion

At this time, Novo Nordisk's Total Stockholder Equity is very stable compared to the past year.

Novo Nordisk Corporate Directors

Kasim KutayDirectorProfile
Sylvie GregoireIndependent DirectorProfile
Mette JensenDirector, Employee RepresentativeProfile
Thomas RantzauDirector, Employee RepresentativeProfile
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.292
Dividend Share
11.4
Earnings Share
3.29
Revenue Per Share
65.202
Quarterly Revenue Growth
0.301
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.